

Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)

On 1 May 2026, Paradigm Biopharmaceuticals Limited (**Company**) completed the issue by way of placement of 73,684,211 fully paid ordinary shares in the capital of the Company (**Shares**) at a price of \$0.19 per Share to institutional and sophisticated investors identified by Bell Potter Securities Limited and Barrenjoey Markets Pty Limited. The placement was previously announced on 27 April 2026.

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 and section 674A of the Corporations Act; and
3. as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act.

As announced on 27 April 2026, the Company intends to undertake a share purchase plan without disclosure to investors under Part 6.2D of the Corporations Act (**SPP**). With regards to the SPP, this notice is also given in accordance with paragraph 7(f) of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*.

Authorised on behalf of the Board of Directors.

Paul Rennie
Managing Director
Paradigm Biopharmaceuticals Ltd.

-Ends